Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | GRN | P28799 | 2/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TPMT | P51580 | 3/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20346113 | 0.88 | MAPT (0.44) | ALOX15TSHRHIF1AGRNSORT1 | |
| SCHEMBL5527447 | 0.86 | TPMT (0.42) | ALOX15TSHRHIF1AGRNSORT1 | |
| SCHEMBL25951737 | 0.86 | ALOX15 (0.41) | ALOX15TSHRHIF1AGRNSORT1 | |
| SCHEMBL18362973 | 0.86 | GABRP (0.43) | ALOX15TSHRHIF1AGRNSORT1 | |
| SCHEMBL15123009 | 0.83 | HCAR3 (0.42) | ALOX15TSHRHIF1AGRNSORT1 | |
| SCHEMBL13636842 | 0.82 | CA5A (0.44) | GRNSORT1KDM4ELMNAALDH1A1 | |
| SCHEMBL7620467 | 0.78 | NPC1 (0.56) | TSHRCA12CA2CA9LMNA | |
| SCHEMBL12098246 | 0.77 | ALOX15 (0.48) | ALOX15TSHRHIF1ARXRARXRB | |
| SCHEMBL166878 | 0.76 | RXRB (0.59) | ALOX15TPMTRXRARXRBRXRG | |
| SCHEMBL501957 | 0.76 | RXRB (0.64) | ALOX15TPMTRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009132453-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| EP-0862555-B1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6610744-B2 | Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition | ALLERGAN, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6534544-B1 | Administering retinoid compound as anticarcinogenic and antitumor agents; side effect reduction | ALLERGAN SALES, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6437129-B1 | ARMOATIC OR HETEROARMOATIC COMPOUND CONTAINING SUBSTITUTED AMIDES OR THIOAMIDES | ALLERGAN SALES, LLC | 2002-08-20 | — | — | US | disclosed |
| US-20020091262-A1 | Substituted aryl or heteroarylamides having retinoid-like biological activity | ALLERGAN | 2002-07-11 | — | — | US | disclosed |
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | ALLERGAN SALES, INC. | 2002-06-20 | — | — | US | disclosed |
| US-6320047-B1 | ACYL- OR THIOACYL-AMINOPYRIDINES | ALLERGAN SALES, INC. | 2001-11-20 | — | — | US | disclosed |
| US-6245786-B1 | ANTIPROLIFERATIVE AGENTS; SKIN DISORDERS | ALLERGAN SALES, INC. | 2001-06-12 | — | — | US | disclosed |
| US-6051713-A | USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION, PARTICULARLY AS AGENTS FOR TREATING SKIN RELATED DISEASES, INCLUDING ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-KERATINIZATION SKIN DISORDERS | ALLERGAN SALES, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-5965606-A | RETINOID RECEPTORS, 2-FLUORO-4-(2',2',4',4'-TETRAMETHYL-8'-TRIFLUOROMETHYLCHROMAN-6' -YL)CARBAMOYL BENZOIC ACID FOR TREATING MONOCYTIC LEUKEMIA | ALLERGAN SALES, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5917048-A | Substituted aryl or heteroarylamides having retinoid-like biological activity | ALLERGAN SALES INC. (US) | 1999-06-29 | — | — | US | disclosed |
| CN-1211180-A | Method of treatment with compounds having RAG 'alpha' receptor specific or selective activity | ALLERGAN CO (US) | 1999-03-17 | — | — | CN | disclosed |
| EP-0869782-A2 | METHODS OF TREATMENT WITH COMPOUNDS HAVING RAR $g(a)? RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY | Vision Pharmaceuticals L.P. (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0862555-A1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5663357-A | COMPOUNDS FOR TREATMENT OF SKIN DISORDERS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
| WO-1997024116-A2 | METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY | VISION PHARMACEUTICALS L.P. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997019062-A1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | RARG, RARA, RARB | ALOX15 850/4885TSHR 103/4885HIF1A 1174/4885 |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1I | ALOX15 3568/4885TSHR 2098/4885HIF1A 4218/4885 |
| US-20020091262-A1 | Substituted aryl or heteroarylamides having retinoid-like biological activity | CCR8, RXRA, CBR1 | ALOX15 2488/4885TSHR 20/4885HIF1A 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.